intrommune_icon_500x500.png
Intrommune Participates in the Forsyth dentech 2021 Conference
September 22, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
intrommune_icon_500x500.png
Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board
September 21, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
22157.jpg
Global Allergy Treatment Markets Report 2021-2026: Allergy Therapeutics and ALK-Abello Dominates the Immunotherapy Segment
September 21, 2021 05:53 ET | Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "Allergy Treatment Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The allergy treatment...
intrommune_icon_500x500.png
Intrommune Therapeutics Announces Arrival of Stuart Loesch as New CCO
September 08, 2021 10:02 ET | Intrommune Therapeutics
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
intrommune_icon_500x500.png
Intrommune Therapeutics Launches #PeanutAllergyStrong
August 24, 2021 12:25 ET | Intrommune Therapeutics
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics Appoints Moises V. “Moe” Vela, Jr. to its Business Advisory Board
August 11, 2021 13:37 ET | Intrommune Therapeutics
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
22157.jpg
Global Food Allergy and Intolerance Products Market Report 2021: Market to Reach $32 Billion by 2027 - Broad Availability of Products Encourage Market Growth
August 09, 2021 08:08 ET | Research and Markets
Dublin, Aug. 09, 2021 (GLOBE NEWSWIRE) -- The "Food Allergy and Intolerance Products - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
intrommune_icon_500x500.png
Intrommune Therapeutics Appoints Sergi Trilla, MD, MBA to its Scientific and Business Advisory Boards
July 28, 2021 14:10 ET | Intrommune Therapeutics
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit
July 22, 2021 16:57 ET | Intrommune Therapeutics
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics to Present at BIO Digital 2021
June 17, 2021 09:11 ET | Intrommune Therapeutics
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...